TICKERNERD
Menu
HTFLHTFLHealthcare · Health Information Services

HTFL Stock Forecast: HeartFlow, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$57
+3.99% on the day

The 9 Wall Street analysts covering HeartFlow, Inc. hold a median 12-month price target of $50 — -11.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$4.9B
Ticker Nerd rank
46/ 100
Median analyst target
$50
Analysts covering
9
Revenue$64.1M+47.6% y/y
Operating income−$17.9M
Net income−$15.7M
Free cash flow−$10.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.3%
1M
+14.7%
YTD
+94.1%
1Y
+66.9%
From 52W high
−6.5%
From 52W low
+176.1%
$20
$61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HTFL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartFlow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
46/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Issuance
71
Momentum
70
Accruals
59
Value
37
Quality
37
Size
23
Volatility
10
Growth
8

Revisions (94): Analysts have, on balance, been raising their forecasts.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HTFL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HTFL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26HTFLHigh $64Median $50Low $39

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $39Median $50High $64

The green dot is the last close — the median target sits −11.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Oct 2026Piper SandlerReiteratesOverweight$45 → $64
22 Sept 2026Canaccord GenuityMaintainsBuy$45 → $56
22 Sept 2026Canaccord GenuityMaintainsBuy—
9 Sept 2026UBSInitiatesNeutral$55
9 Sept 2026UBSInitiatesNeutral—
14 Aug 2026Canaccord GenuityMaintainsBuy$37 → $45
14 Aug 2026Canaccord GenuityMaintainsBuy—
14 Aug 2026JP MorganMaintainsOverweight$35 → $45
14 Aug 2026JP MorganMaintainsOverweight—
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$35 → $40
14 Aug 2026Morgan StanleyMaintainsEqual-Weight—
14 Aug 2026Piper SandlerReiteratesOverweight—
14 Aug 2026Piper SandlerReiteratesOverweight$38 → $45
14 Aug 2026StifelMaintainsBuy—
14 Aug 2026StifelMaintainsBuy$40 → $45
14 Aug 2026Wells FargoMaintainsOverweight$37 → $39
14 Aug 2026Wells FargoMaintainsOverweight—
31 July 2026BairdInitiatesOutperform$34
31 July 2026BairdInitiatesOutperform—
1 July 2026Freedom Capital MarketsInitiatesBuy$37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HTFL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HTFL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, HeartFlow, Inc. returned +66.9% against +14.8% for the S&P 500, dividends included.

HTFL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26HTFLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HTFL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

HeartFlow, Inc. (HTFL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.8×

Cheaper than 96% of US stocks

Price / sales
23.2×

Cheaper than 8% of US stocks

Price / book
17.5×

Cheaper than 5% of US stocks

EV / EBITDA
−67.0×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
47.6%

Higher than 85% of US stocks

Earnings growth (YoY)
47.6%

Higher than 74% of US stocks

Gross margin
83.0%

Higher than 93% of US stocks

Operating margin
−27.9%

Higher than 20% of US stocks

Net margin
−55.8%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−154.2%

Higher than 9% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HeartFlow, Inc. (HTFL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HeartFlow, Inc. has a market value of $4.9B and an enterprise value of $4.8B.

  • Revenue in the twelve months to 30 June 2026: $212.1M. The latest quarter grew 47.6% year on year.

  • Net income over the same four quarters: −$118.4M, a −55.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.83.

  • Free cash flow in the twelve months to 30 June 2026: −$59.2M.

  • Shares outstanding: 86.7M.

  • Trailing P/E: −17.8×; forward P/E: −208.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • HeartFlow, Inc. employs 843 people — $252K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

HTFL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HTFLHeartFlow, Inc.$4.9B46
WAYWaystar Holding Corp.$5.7B40
DOCSDoximity, Inc.$6.4B73
PRVAPrivia Health Group, Inc.$2.8B59
HQYHealthEquity, Inc.$9.3B95
HNGEHinge Health, Inc.$9.4B86
SDGRSchrödinger, Inc.$2.1B62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartFlow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HTFL news & analysis

AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry

GlobeNewsWire · 2 Nov 2026positive

HeartFlow reported that its plaque analysis in the prospective DECIDE Registry was associated with 34% fewer major cardiovascular events and half the rate of heart attack at one year. The source also noted that approximately 50% of patients reached LDL-C goals by 90 days.

Why it matters — The reported prospective outcomes data may be relevant to HTFL watchers assessing clinical evidence for HeartFlow’s plaque analysis.

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

GlobeNewsWire · 1 Nov 2026positive

The randomized P4 study, presented at TCT 2026 and published in NEJM, found CT-guided PCI delivered clinical outcomes at one year matching IVUS, with shorter procedures. Heartflow PCI Navigator changed PCI plans in approximately 70% of patients.

Why it matters — The findings highlight the potential relevance of CT-based planning and Heartflow PCI Navigator to PCI decision-making.

Boston Scientific announces results for third quarter 2026

PRNewsWire · 28 Oct 2026neutral

Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% on a reported, operational and organic basis compared with the prior-year period.

Why it matters — The excerpt reports results for Boston Scientific, but does not describe any direct effect on HeartFlow.

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

GlobeNewsWire · 19 Oct 2026neutral

Heartflow announced it will report third-quarter 2026 financial results after market close on November 12, 2026. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the results.

Why it matters — HTFL watchers can note the scheduled release and conference call as an upcoming opportunity to hear the company's quarterly results and management discussion.

HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High

The Motley Fool · 15 Sept 2026neutral

HeartFlow's CEO sold 38,900 shares for approximately $1.8 million at a weighted average price of $46.78 per share, representing 11% of the executive's pre-filing equity stake, after the stock reached a 52-week high.

Why it matters — Insider selling by a CEO after a stock hits a 52-week high can draw investor attention to whether the move signals the executive's view on the company's valuation.

FAQ

Frequently asked questions about HTFL stock

What is the HTFL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering HeartFlow, Inc. have a median 12-month price target of $50, with estimates ranging from $39 to $64. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HTFL stock a buy right now?

Of the 9 analysts covering HeartFlow, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartFlow, Inc. 46 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HTFL?

As at 4 Nov 2026, HeartFlow, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will HTFL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -11.6% from the last close, and Ticker Nerd's factor model ranks HeartFlow, Inc. 46 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HTFL stock forecast for 2030?

No analyst covering HeartFlow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HTFL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $39 to $64 over the next 12 months.

How has HTFL stock performed over the past year?

HeartFlow, Inc. returned +66.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartFlow, Inc. do?

HeartFlow Inc. is a commercial-stage medical technology company focused on non-invasive coronary artery disease diagnosis and management.

What is the latest news on HTFL?

The most recent item we track (GlobeNewsWire, 2 Nov 2026): "AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry". HeartFlow reported that its plaque analysis in the prospective DECIDE Registry was associated with 34% fewer major cardiovascular events and half the rate of heart attack at one year. The source also noted that approximately 50% of patients reached LDL-C goals by 90 days.

Company

About HeartFlow, Inc.

HeartFlow Inc. is a commercial-stage medical technology company focused on non-invasive coronary artery disease diagnosis and management. HeartFlow Inc. develops software and artificial intelligence tools that analyze coronary computed tomography angiography scans to create personalized 3D models of a patient’s heart, helping physicians assess blood flow, stenosis, plaque volume, and plaque composition. Its main products include HeartFlow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis, which support clinical decision-making across the coronary care pathway. The company serves hospitals, cardiology practices, and healthcare systems in the United States and selected international markets, with its platform used to improve precision in cardiovascular assessment and treatment planning. Headquartered in San Francisco, California, HeartFlow Inc. operates at the intersection of medical imaging, digital health, and cardiovascular diagnostics.

CEO Mr. John C.M. Farquhar · 843 employees · United States · https://www.heartflow.com